Triple-negative breast cancer: discussing treatment before surgery

Being offered drug treatment before an operation for triple-negative breast cancer can feel as though surgery is being delayed. In suitable circumstances, however, this is an intentional first phase: treatment acts on the cancer before removal and provides information about its response. The subtype name alone does not mean everyone needs preoperative treatment. Tumour size, lymph node findings, stage and general health all matter. This article concerns non-metastatic disease in which surgery is being considered as part of treatment. Stage IV disease requires a separate discussion of treatment goals and options.

What “triple-negative” actually describes

The term concerns tests on the cancer cells: oestrogen and progesterone receptors are negative, and HER2 is not positive. It does not mean three tumours or a particular cancer stage. Two people with this subtype can have very different disease extent and treatment pathways.

Include the complete receptor and HER2 reports in a consultation pack, rather than just a note saying “TNBC”. If a result is provisional, the sample was limited or two laboratories disagreed, make that clear before the regimen is selected. The biomarker findings help explain why endocrine therapy and standard approaches for HER2-positive cancer are not automatically suitable.

What treatment before surgery can achieve

The NCI treatment overview describes preoperative chemotherapy as an approach for larger tumours, sometimes with immunotherapy when appropriate. Goals include shrinking the cancer and improving the options for subsequent local treatment. A smaller tumour may have a different sequence. A drug list on a hospital website cannot establish the right plan for an individual patient.

Before the first treatment, it helps to understand how the surgical phase is being planned: the intended operation, how the original tumour area has been documented and who will assess response. Shrinkage on imaging gives the team useful information, but a scan does not replace examination of tissue. A lump becoming impossible to feel is not a reason to cancel planned surgery independently.

Why the pathology after treatment matters

Following surgery, the pathologist examines the removed breast tissue and sampled nodes. No residual invasive cancer in the examined material and residual invasive disease are different findings that can inform the next phase. A “complete response” does not promise that the cancer will never return. It also does not automatically remove every remaining part of the planned treatment.

If residual cancer is found, the oncologist considers further treatment in the context of medicines already received, tolerability and other relevant information, including inherited BRCA findings when tested. Ask for a written distinction between treatment that was planned from the beginning and changes being proposed specifically because of the surgical pathology. That makes an updated recommendation easier to understand and compare.

Keeping the pathway connected across countries

An operation booked in Turkey should not leave the earlier drug-treatment period without a responsible clinician at home. The teams need actual administration dates, medicine names, complications and assessment results. If a dose changed or a cycle was postponed, the transferred record should include the change and its reason, rather than only the original schedule.

Before travelling, establish where interim assessments will happen, who confirms readiness for surgery and how the second team will receive the final pathology. The arrangements matter particularly when a surgical visit is only one part of a longer course. Written responsibilities reduce the risk of each hospital assuming that the other will arrange the next appointment.

Immunotherapy has its own eligibility requirements and adverse effects. Describing a drug as modern does not establish that it is appropriate or available at a particular hospital. New significant symptoms during treatment should be discussed promptly with the treating team rather than held back for an overseas consultation.

A useful request when arranging an oncology assessment in Turkey is to review the sequence before and after surgery using the complete records. The resulting explanation should make the purpose of each phase, possible reasons for changing course and the clinician responsible for each transition clear.